

**Analysis of Covariance (ANCOVA) of Change from Baseline in
Fasting Glucose (mmol/L) at Week 24 (LOCF)
Efficacy Analysis Population**

Treatment Group	Baseline		Week 24 (LOCF)		Change from Baseline			LS Mean (95% CI)^a
	N	Mean (SD)	N	Mean (SD)	N	Mean (SD)		
Placebo	79	5.7 (2.23)	79	5.6 (1.65)	79	-0.0 (2.32)	0.07 (-0.26, 0.41)	
Xanomeline Low Dose	79	5.4 (0.95)	79	5.4 (1.06)	79	-0.1 (1.02)	-0.11 (-0.44, 0.23)	
Xanomeline High Dose	74	5.4 (1.37)	74	5.8 (2.21)	74	0.4 (1.65)	0.39 (0.04, 0.74)	
Pairwise Comparison			Difference in LS Mean (95% CI)^a				p-Value^b	
Xanomeline Low Dose vs. Placebo			-0.18 (-0.65, 0.30)				0.4670	
Xanomeline High Dose vs. Placebo			0.32 (-0.17, 0.80)				0.2004	

^aLS means and differences in LS means are based on an ANCOVA model with treatment and baseline glucose as covariates.
^bp-values are from the ANCOVA model testing treatment effects (overall F-test p-value: 0.0000).
 LOCF (Last Observation Carried Forward) approach is used for missing Week 24 values.
 ANCOVA = Analysis of Covariance; CI = Confidence Interval; LS = Least Squares; SD = Standard Deviation

Source: ADLBC Analysis Dataset

Analysis conducted: 06NOV2025

Statistical software: Python (statsmodels)